2008
DOI: 10.1093/jjco/hyn003
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background:A pre-clinical study demonstrated that paclitaxel induced thymidine phosphorylase in the tumor tissues. The combination of paclitaxel and doxifluridine is expected to exert extra anti-tumor effects. We evaluated the efficacy of this combination in patients with unresectable or recurrent gastric cancer who had been previously treated with S-1. Methods: Registration was started to enroll 35 patients with advanced/recurrent gastric cancer, who were selected among those with measurable lesions fitting t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
12
0

Year Published

2009
2009
2012
2012

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 23 publications
(14 citation statements)
references
References 12 publications
2
12
0
Order By: Relevance
“…Many phase II studies have also been performed to investigate the safety profi le and effectiveness of weekly paclitaxel-containing combination therapies for advanced and metastatic gastric cancers (Table 4) [ [45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61].…”
Section: Weekly Administration Of Paclitaxelmentioning
confidence: 99%
“…Many phase II studies have also been performed to investigate the safety profi le and effectiveness of weekly paclitaxel-containing combination therapies for advanced and metastatic gastric cancers (Table 4) [ [45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61].…”
Section: Weekly Administration Of Paclitaxelmentioning
confidence: 99%
“…Among these two, only doxifl uridine is available for the treatment of gastric cancer in Japan. As a combination of this drug with paclitaxel has already been explored [19], the authors chose to explore a combination with docetaxel. The response rate of this combination chemotherapy was lower than expected, at 17.5%, and our statistical hypothesis in this phase II study was not met.…”
Section: Discussionmentioning
confidence: 99%
“…Most recently reported studies of second-line chemotherapy consist of small-scale phase II or retrospective trials [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. No randomized control trial to establish standard treatment has been conducted.…”
Section: Regional Differences In Second-line Chemotherapy and New Issmentioning
confidence: 99%
“…However, the effects of monotherapy are limited [20][21][22][23][24][25]. Various combination therapies have been investigated in small-scale, phase II studies [26][27][28][29][30][31][32][33]. However, according to the results of some recent studies, the response rates ranged from approximately 10 to 20%, and PFS ranged from 2.5 to 4.0 months.…”
Section: Regional Differences In Second-line Chemotherapy and New Issmentioning
confidence: 99%